- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07647315
Wireless Implantable Mandarin Chinese Speech Neuroprosthesis Evaluation (WISE)
8 september 2026 uppdaterad av: Shanghai StairMed Technology Co., Ltd.
This prospective, single-arm clinical trial is designed to preliminarily evaluate the safety and efficacy of an implantable wireless brain-computer interface (BCI) system (manufactured by Shanghai StairMed Technology Co., Ltd.) in enabling subjects with speech disorders to achieve brain-controlled interaction and communication.
Eligible subjects will undergo surgical implantation of the device and receive brain-control training.
All participants will be followed for an expected period of 12 months.
During the follow-up, adverse events, serious adverse events, and device deficiencies will be recorded, and efficacy data on brain-controlled interaction and communication will be collected.
The goal is to conduct an initial assessment of the safety and effectiveness of the investigational device in achieving brain-controlled effects in the target population.
Studieöversikt
Studietyp
Interventionell
Inskrivning (Beräknad)
4
Fas
- Inte tillämpbar
Kontakter och platser
Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.
Studiekontakt
- Namn: Clinical team Stairmed
- Telefonnummer: +86 021-80510178
- E-post: yumiao@stairmed.com
Studieorter
-
-
Shanghai Municipality
-
Shanghai, Shanghai Municipality, Kina
- Rekrytering
- Huashan Hospital, Fudan University
-
Kontakt:
- Ying Mao, Ph.D
- Telefonnummer: +86 021 5288 8045
- E-post: maoying@fudan.edu.cn
-
-
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
- Vuxen
- Äldre vuxen
Tar emot friska volontärer
Nej
Beskrivning
Inclusion Criteria:
- Age 18 to 80 years (inclusive), any gender.
- Clinically diagnosed with speech disorders, including locked-in syndrome, severe dysarthria, aphasia with preserved auditory comprehension, or late-stage ALS-related language dysfunction, secondary to stroke, traumatic brain injury, amyotrophic lateral sclerosis (ALS), or other motor neuron diseases.
- The subject, or the subject with the assistance of their legal representative, is willing to follow the investigator's instructions, adhere to all protocol-specified procedures, and complete all required follow-up.
- The subject and their legal representative fully understand the purpose and significance of the trial; the subject voluntarily agrees to participate and signs the informed consent form
Exclusion Criteria:
- Subjects with any previously implanted metallic objects or devices (e.g., pacemakers, defibrillators, neurostimulators, cochlear implants), except for dental metal implants or implants assessed to have no impact on the trial.
- Subjects who have been on long-term anticoagulant or antiplatelet therapy prior to screening, with antiplatelet drugs discontinued for less than 2 weeks before surgery; or subjects with hematological or autoimmune disorders (e.g., aplastic anemia, systemic lupus erythematosus); or subjects with clinically significant coagulation test abnormalities during the screening period.
- Subjects assessed by an anesthesiologist to be unable to tolerate anesthesia and surgery.
- Subjects assessed by the investigator to have nervous system diseases (e.g., cerebrovascular lesions, intracranial infections, neurodegenerative diseases, epilepsy) or a history of craniocerebral trauma, resulting in severe brain function impairment or marked EEG abnormalities.
- Subjects with physiological or pathological conditions that may lead to poor healing of scalp wounds.
- Subjects in the acute infection phase or suffering from other severe infections.
- Subjects with cognitive impairment or psychotic symptoms.
- Subjects with severe dysfunction of vital organs (heart, lung, liver, kidney, etc.), malignant tumors or autoimmune diseases, who are deemed ineligible for this clinical trial by investigators.
- Subjects judged by investigators to have an expected survival time of less than 1 year.
- Subjects with drug abuse or alcohol dependence.
- Pregnant or breastfeeding women, or subjects planning to become pregnant during the trial period.
- Subjects currently participating in clinical trials of drugs or other medical devices.
- Subjects unable to understand or read Chinese.
- Other circumstances under which investigators consider the subject unsuitable to participate in this clinical trial
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Enhetens genomförbarhet
- Tilldelning: N/A
- Interventionsmodell: Enskild gruppuppgift
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Implantation of the WRS
|
WRS is a minimally invasive, wireless brain-machine interface system.
Subjects with speech disorders undergo implantation of WRS, receive brain-control training, and are followed up.
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Incidence of Device-Related Adverse Events
Tidsram: From implantation to Month 12
|
Adverse events determined by the investigator to be related to the investigational device, recorded throughout the study period.
|
From implantation to Month 12
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Incidence of All Adverse Events
Tidsram: From implantation to Month 12
|
From implantation to Month 12
|
|
|
Incidence of Device Deficiencies
Tidsram: From implantation to Month 12
|
From implantation to Month 12
|
|
|
Number of Reliable Recording Channels at Each Evaluation Time Point
Tidsram: At 3, 6, 9, and 12 months post-implantation
|
At 3, 6, 9, and 12 months post-implantation
|
|
|
Speech Output Rate in Characters Per Minute (CPM)
Tidsram: At 3, 6, 9, and 12 months post-implantation
|
The speech output rate, defined as the number of Chinese characters produced per unit time during task performance, is calculated and documented every 3 months during the follow-up period.
|
At 3, 6, 9, and 12 months post-implantation
|
|
Speech Output Character Error Rate (CER)
Tidsram: At 3, 6, 9, and 12 months post-implantation
|
The subject independently outputs the complete sequence of Chinese characters from a standard reference text.
The minimum edit distance (total substitutions, deletions, and insertions) between the decoded sequence and the reference sequence is divided by the total number of Chinese characters in the reference text to obtain the character error rate.
Recorded every 3 months during follow-up.
|
At 3, 6, 9, and 12 months post-implantation
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart (Faktisk)
1 september 2026
Primärt slutförande (Beräknad)
30 augusti 2028
Avslutad studie (Beräknad)
30 december 2028
Studieregistreringsdatum
Först inskickad
9 juni 2026
Först inskickad som uppfyllde QC-kriterierna
9 juni 2026
Första postat (Faktisk)
15 juni 2026
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
11 september 2026
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
8 september 2026
Senast verifierad
1 september 2026
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- STAIRSUP-201
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Nej
Studerar en amerikansk FDA-reglerad produktprodukt
Nej
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .